Is Lakefront Biotherapeutics a good investment? Lakefront Biotherapeutics (LKFT.AS) is currently trading at 30.18 EUR. Market analysts have a consensus price target of 31.46 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 3.51. This relatively low multiple may signal that Lakefront Biotherapeutics is undervalued compared to historical market norms.
Earnings Schedule: Lakefront Biotherapeutics is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -4.95.
No, it does not currently pay a dividend.
Lakefront Biotherapeutics is classified as a Stock. You can compare it against 9 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of 9.02.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Community Discussion